Sfoglia per Autore
Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds
2007-01-01 Federica Di Nicolantonio; Sabrina Arena; Margherita Gallicchio; Miriam Martini; Davide Zecchin; Simona Flonta; Giulia Stella; Giovanni Appendino; Roberto Fantozzi; Enzo Medico; Alberto Bardelli
Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers
2007-01-01 ARENA S; ISELLA C; MARTINI M; DE MARCO A; MEDICO E; BARDELLI A
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
2008-01-01 Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
2008-01-01 Di Nicolantonio F ; Arena S; Gallicchio M; Zecchin D; Martini M; Flonta SE; Stella GM; Lamba S; Cancelliere C; Russo M; Geuna M; Appendino G; Fantozzi R; Medico E; Bardelli A
BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer
2008-01-01 Di Nicolantonio F; Martini M; Molinari F; Bianchi AS; Arena S; Saletti P; Mazzucchelli L; Frattini M; Siena S; Bardelli A
EVALUATION OF DRUG RESPONSES IN NON-TRANSFORMED CELLS CARRYING CANCER ALLELES
2009-01-01 Gallicchio M; Di Nicolantonio F; Arena S.; Zecchin D; Martini M; Flonta S; Stella G; Lamba S; Cancelliere C; Russo M; Geuna M; Appendino G; Fantozzi R; Medico E; Bardelli A.
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
2009-01-01 Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer
2009-01-01 Sartore-Bianchi A*; Di Nicolantonio F*; Nichelatti M; Molinari F; De Dosso S; Saletti P; Martini M; Cipani T; Marrapese G; Mazzucchelli L; Lamba S; Veronese S; Frattini M; Bardelli A;^ Siena S^ (*shared first authorship; ^shared last authorship)
MLK4 gene, a new diagnostic and prognostic marker in cancers
2010-01-01 Alberto Bardelli; Miriam Martini
Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective population-based Consortium analysis
2010-01-01 De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
2010-01-01 Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S
Targeted therapies: how personal should we go?
2012-01-01 Martini M; Vecchione L; Siena S; Tejpar; Bardelli A
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia
2012-01-01 Bottos A; Martini M; Di Nicolantonio F; Comunanza V; Maione F; Minassi A; Appendino G; Bussolino F; Bardelli A.
PI3K keeps the balance between metabolism and cancer.
2012-01-01 Braccini L;Ciraolo E;Martini M;Pirali T;Germena G;Rolfo K;Hirsch E
Targeting PI3K in Cancer: Any Good News?
2013-01-01 Miriam Martini;Elisa Ciraolo;Federico Gulluni;Emilio Hirsch
Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis
2013-01-01 M. Martini; M. Russo; S. Lamba; E. Vitiello; E. H. Crowley; F. Sassi; D. Romanelli; M. Frattini; A. Marchetti; A. Bardelli
Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells
2013-01-01 Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A.
BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
2013-01-01 Zecchin D;Boscaro V;Medico E;Barault L;Martini M;Arena S;Cancelliere C;Bartolini A;Crowley EH;Bardelli A;Gallicchio M;Di Nicolantonio F
PI3K/AKT signaling pathway and cancer: an updated review.
2014-01-01 Martini M;De Santis MC;Braccini L;Gulluni F;Hirsch E
PI3K in cancer-stroma interactions: bad in seed and ugly in soil.
2014-01-01 Hirsch E;Ciraolo E;Franco I;Ghigo A;Martini M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds | 2007 | Federica Di Nicolantonio; Sabrina Arena; Margherita Gallicchio; Miriam Martini; Davide Zecchin; Simona Flonta; Giulia Stella; Giovanni Appendino; Roberto Fantozzi; Enzo Medico; Alberto Bardelli | |
| Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers | 2007 | ARENA S; ISELLA C; MARTINI M; DE MARCO A; MEDICO E; BARDELLI A | |
| Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer | 2008 | Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A | |
| Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses | 2008 | Di Nicolantonio F ; Arena S; Gallicchio M; Zecchin D; Martini M; Flonta SE; Stella GM; Lamba S; Cancelliere C; Russo M; Geuna M; Appendino G; Fantozzi R; Medico E; Bardelli A | |
| BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer | 2008 | Di Nicolantonio F; Martini M; Molinari F; Bianchi AS; Arena S; Saletti P; Mazzucchelli L; Frattini M; Siena S; Bardelli A | |
| EVALUATION OF DRUG RESPONSES IN NON-TRANSFORMED CELLS CARRYING CANCER ALLELES | 2009 | Gallicchio M; Di Nicolantonio F; Arena S.; Zecchin D; Martini M; Flonta S; Stella G; Lamba S; Cancelliere C; Russo M; Geuna M; Appendino G; Fantozzi R; Medico E; Bardelli A. | |
| PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies | 2009 | Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A | |
| Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer | 2009 | Sartore-Bianchi A*; Di Nicolantonio F*; Nichelatti M; Molinari F; De Dosso S; Saletti P; Martini M; Cipani T; Marrapese G; Mazzucchelli L; Lamba S; Veronese S; Frattini M; Bardelli A;^ Siena S^ (*shared first authorship; ^shared last authorship) | |
| MLK4 gene, a new diagnostic and prognostic marker in cancers | 2010 | Alberto Bardelli; Miriam Martini | |
| Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective population-based Consortium analysis | 2010 | De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S | |
| Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer | 2010 | Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S | |
| Targeted therapies: how personal should we go? | 2012 | Martini M; Vecchione L; Siena S; Tejpar; Bardelli A | |
| Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia | 2012 | Bottos A; Martini M; Di Nicolantonio F; Comunanza V; Maione F; Minassi A; Appendino G; Bussolino F; Bardelli A. | |
| PI3K keeps the balance between metabolism and cancer. | 2012 | Braccini L;Ciraolo E;Martini M;Pirali T;Germena G;Rolfo K;Hirsch E | |
| Targeting PI3K in Cancer: Any Good News? | 2013 | Miriam Martini;Elisa Ciraolo;Federico Gulluni;Emilio Hirsch | |
| Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis | 2013 | M. Martini; M. Russo; S. Lamba; E. Vitiello; E. H. Crowley; F. Sassi; D. Romanelli; M. Frattini; A. Marchetti; A. Bardelli | |
| Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells | 2013 | Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A. | |
| BRAF V600E is a determinant of sensitivity to proteasome inhibitors. | 2013 | Zecchin D;Boscaro V;Medico E;Barault L;Martini M;Arena S;Cancelliere C;Bartolini A;Crowley EH;Bardelli A;Gallicchio M;Di Nicolantonio F | |
| PI3K/AKT signaling pathway and cancer: an updated review. | 2014 | Martini M;De Santis MC;Braccini L;Gulluni F;Hirsch E | |
| PI3K in cancer-stroma interactions: bad in seed and ugly in soil. | 2014 | Hirsch E;Ciraolo E;Franco I;Ghigo A;Martini M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile